Scarica l'app Stockscreener
0.6354
0.68%
0.0043
Precedente Chiudi:
$0.6311
Aprire:
$0.6267
Volume 24 ore:
247.69K
Relative Volume:
1.47
Capitalizzazione di mercato:
$21.21M
Reddito:
$454.00K
Utile/perdita netta:
$-21.72M
Rapporto P/E:
-1.1906
EPS:
-0.5337
Flusso di cassa netto:
$-25.74M
1 W Prestazione:
-4.44%
1M Prestazione:
-6.05%
6M Prestazione:
+8.63%
1 anno Prestazione:
-32.43%
Intervallo 1D:
$0.6231
$0.6609
Intervallo di 1 settimana:
$0.61
$0.665
Portata 52W:
$0.2805
$1.96
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Nome
Vyne Therapeutics Inc
Settore
Industria
Telefono
800-775-7936
Indirizzo
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
0.6354 | 21.21M | 454.00K | -21.72M | -25.74M | -0.5337 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-11-18 | Iniziato | BTIG Research | Buy |
| 2021-12-06 | Ripresa | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Borsa (VYNE) Ultime notizie
Vyne Therapeutics Inc (VYNE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vyne Therapeutics Inc (VYNE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vyne Therapeutics Inc (VYNE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Vyne Therapeutics Inc (VYNE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vyne Therapeutics Inc (VYNE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vyne Therapeutics Inc (VYNE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vyne Therapeutics Inc (VYNE) Institutional Confidence - TradingKey
Vyne Therapeutics Inc (VYNE) Valuation: PE, PB & Fair Value Analysis - TradingKey
[EFFECT] VYNE Therapeutics Inc. SEC Filing - Stock Titan
Vyne Therapeutics Inc (VYNE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VYNE (VYNE) merger with Yarrow: $100M financing, 35.8441 exchange ratio - Stock Titan
Zhang Xiaofan discloses 1.87M shares (5.6%) in VYNE Therapeutics (VYNE) - Stock Titan
VYNE Q1 2026 Earnings: EPS Beat Estimate, No Revenue ReportedFinancial Summary - newsline.com
VYNE Therapeutics (VYNE) Edges Higher in Quiet Trading, Testing Key Resistance at $0.69New Listing Stocks - newsline.com
VYNE Therapeutics (VYNE) Consolidates Near Support After Slight PullbackMACD Signal Stocks - newsline.com
[Form 4] VYNE Therapeutics Inc. Insider Trading Activity - Stock Titan
VYNE Therapeutics (VYNE) Posts Modest Gain, Holds Above Key SupportMotive Wave - newsline.com
VYNE Therapeutics (VYNE) Edges Lower as Shares Test Key Support Near $0.65Standard Deviation - thelegaladvocate.com
VYNE Highlights Yarrow Merger Strategy and Endocrine Pipeline - TipRanks
VYNE to Advance YB-101 into Phase 2 in Q2 2026; $200M Raised, Phase 2a Readout Expected H2 2027 - TradingView
Yarrow reverse merger refocuses VYNE (NASDAQ: VYNE) with $200M war chest - Stock Titan
VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04 - MSN
VYNE SEC FilingsVyne Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nantahala (NASDAQ: VYNE) reports 2,000,000-share stake representing 6.00% - Stock Titan
Yarrow merger to refocus VYNE (NASDAQ: VYNE) with $200M financing - Stock Titan
MSN Money - MSN
TradingKey - TradingKey
Vyne Therapeutics Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
The regulatory exposure in VYNE Therapeutics (VYNE) results | Q4 2025: Earnings Beat EstimatesNon-GAAP Earnings - The Legal Advocate
VYNE Therapeutics (NASDAQ: VYNE) to become Yarrow Bioscience after merger - Stock Titan
VYNE Therapeutics Inc. (VYNE) beats Q4 2025 EPS expectations significantly, yet shares edge slightly lower in today's trading.Special Dividend - UBND thành phố Hải Phòng
VYNE Therapeutics Inc. (VYNE) reports narrower Q4 2025 loss than estimates, yet shares dip slightly in today’s trading.Post Announcement - Xã Vĩnh Công
VYNE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VYNE Therapeutics (VYNE) Stock: Market Structure Shift (+3.21%) 2026-04-20Hull Moving Average - newsline.com
Is VYNE Therapeutics (VYNE) stock suitable for new investors (Technical Weakness) 2026-04-18Sell Signals - UBND thành phố Hải Phòng
Death Cross: Is VYNE Therapeutics Inc a play on infrastructure spending2026 Movers & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Pulse: Can VYNE Therapeutics Inc expand its profit margins2026 Retail & Weekly High Return Forecasts - baoquankhu1.vn
Breakout Watch: Can VYNE Therapeutics Inc deliver consistent dividends2026 Big Picture & Real-Time Market Sentiment Reports - baoquankhu1.vn
Layoff Watch: Can VYNE Therapeutics Inc sustain earnings growthMarket Performance Report & Momentum Based Trading Signals - baoquankhu1.vn
How does VYNE Therapeutics (VYNE) Stock react to Fed policy | Price at $0.61, Down 0.57%Crowd Breakout Signals - Newser
Weekly Earnings: Is VYNE Therapeutics Inc stock showing strong momentumWeekly Loss Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Vyne Therapeutics Inc Azioni (VYNE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):